veralipride
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Induces prolactin secretion without any estrogenic or progestagenic effects.
Chemistry & pharmacology
Loading structure…
SMILES
C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC- Mol. weight
- 383.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105581 ↗
Also known as
- agreal
- agreal
- agreal
- agréal
- menofel
- n-(1-allyl-2-pyrrolidinyl)methyl-2,3-dimethoxy-5-sulfamoylbenzamide
- veraligral
- veralipride
- veralipride
- veralipride
- veralipride
- veralipride
- veralipride
- veralipride
- (+/-)-veralipride
- veralipride monohydrochloride